Frost & Sullivan Presents the Unprecedented Opportunities in the Personal Protection Equipment Industry

The COVID-19 pandemic has caught the world by surprise, and a shortage of personal protective equipment (PPE) has exposed the vulnerability of our healthcare and emergency response systems. While the virus has uncovered industry shortcomings, such as its dependence on outsourced supply chains, demand for PPE is thriving and creating market opportunities globally.

According to Frost & Sullivan, on average, the industry grows at 3% to 5% per annum; however, the healthcare PPE segment is now experiencing an unprecedented boom, estimated at 80% to 100%, and is opening doors for new entrants, alliances, and partnership opportunities between PPE players and material suppliers.

Frost & Sullivan invites you to join Global President & Managing Partner Aroop Zutshi and Vice President Sanjiv Bhaskar for the Growth Opportunity briefing, “COVID-19: Growth Opportunities in the PPE Industry,” on May 7 at 11 a.m. EST.

Frost & Sullivan notes the briefing will highlight how the PPE industry can seize the growth opportunities presented and remain a favorite of the private equity community, and also discuss how the pandemic will change the PPE industry’s approach to different end-user industries.

For more information and to register for the webinar, please visit: https://frost.ly/42t

Key benefits of attending this webinar:

  • Understand the impact of COVID-19 on the industrial PPE markets.
  • Identify global opportunities for industrial PPE supplies of masks, gowns and eye protection in the healthcare industry.
  • Expose potential new competitors to industrial PPE players.
  • Discover how to overcome supply chain challenges such as over-dependence on imports.
  • Capitalize on the growing userbase to help your company expand.
  • Find out if COVID-19 will reverse the PPE consolidation trend or enhance it.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”